We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
This observational study included 4252 adult patients admitted to a single center in Bronx, New York from March 1, 2020 to May 2, 2020. Among non-diabetic patients, statin use did not significantly impact in-hospital mortality. Among diabetic patients on a statin, reduced cumulative in-hospital mortality was observed (24% vs 39%, P < .01). After propensity score matching and inverse probability treatment weighting, the risk of death during hospitalization was 12% lower for statin users than non-users.
In hospitalized COVID-19 patients with diabetes, statin use was associated with reduced in‐hospital mortality. If confirmed, these study findings may highlight the importance of administering statins to patients with diabetes and COVID-19.
This abstract is available on the publisher's site.
Severe coronavirus disease (COVID-19) is characterized by a pro-inflammatory state with high mortality. Statins have anti-inflammatory effects and may attenuate the severity of COVID-19.
Methods and Results
An observational study of all consecutive adult patients with COVID-19 from March 1, 2020 to May 2, 2020 admitted to a single-center located in Bronx, New York. Patients were grouped as those that did and did not receive a statin and in-hospital mortality was compared by competing events regression. In addition, propensity score matching and inverse probability treatment weighting (IPTW) were used in survival models to examine the association between statin use and death during hospitalization. A total of 4,252 patients were admitted with COVID-19. Diabetes modified the association between statin use and in-hospital mortality. Patient with diabetes on a statin (n=983) were older (69±11 vs. 67±14 years, p<0.01), had lower inflammatory markers (C-reactive protein: 10.2, IQR: 4.5-18.4 vs. 12.9, IQR: 5.9-21.4 mg/dl, p<0.01) and reduced cumulative in-hospital mortality (24% vs. 39%, p<0.01) than those not on a statin (n=1,283). No difference in hospital mortality was noted in patients without diabetes on or off statin (20% vs. 21%, p=0.82). Propensity score matching (HR=0.88, 95% CI 0.83-0.94, p<0.01) and IPTW (HR=0.88, 95% CI 0.84-0.92, p<0.01) showed a 12% lower risk of death during hospitalization for statin users than non-users.
Statin use was associated with reduced in-hospital mortality from COVID-19 in patients with diabetes. These findings, if validated, may further reemphasize administration of statins to patients with diabetes during the COVID-19 era.